Cardiovascular complications of chemotherapy
AbstractMany of the highly effective agents in contemporary oncology, including the anthracyclines and trastuzumab, are known to increase the risk of cardiac events in both the short and long term. As these agents are often used to obtain a cure, the means of maximising their benefits while reducing the risk to the heart has become a priority when managing the patient with a malignancy. In addition, the novel biologic therapies, designed to fulfil unmet needs in oncology, require the development of strategies for risk detection and management that aim to reduce the risk of cardiac toxicity.
Copyright (c) 2017 SA Heart Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This journal is an open access journal, and the authorsÂ and journal should be properly acknowledged, when works are cited.
Authors may use the publishers version for teaching purposes, in books, theses, dissertations, conferences and conference papers.Â
A copy of the authors’ publishers version may also be hosted on the following websites:
- Non-commercial personal homepage or blog.
- Institutional webpage.
- Authors Institutional Repository.Â
The following notice should accompany such a posting on the website: “This is an electronic version of an article published in SAHJ, Volume XXX, number XXX, pages XXX–XXX”, DOI.Â Authors should also supply a hyperlink to the original paper or indicate where the original paper (http://www.journals.ac.za/index.php/SAHJ) may be found.Â
Authors publishers version, affiliated with the Stellenbosch University will be automatically deposited in the University’s’ Institutional Repository SUNScholar.
Articles as a whole, may not be re-published with another journal.
Copyright Holder: SA Heart Journal
The following license applies:
Attribution CC BY-NC-ND 4.0